Interleukin-12: Biological properties and clinical application

Michele Del Vecchio, Emilio Bajetta, Stefania Canova, Michael T. Lotze, Amy Wesa, Giorgio Parmiani, Andrea Anichini

Research output: Contribution to journalArticle

389 Citations (Scopus)

Abstract

Interleukin-12 (IL-12) is a heterodimeric protein, first recovered from EBV-transformed B cell lines. It is a multifunctional cytokine, the properties of which bridge innate and adaptive immunity, acting as a key regulator of cell-mediated immune responses through the induction of T helper 1 differentiation. By promoting IFN-γ production, proliferation, and cytolytic activity of natural killer and T cells, IL-12 induces cellular immunity. In addition, IL-12 induces an antiangiogenic program mediated by IFN-γ-inducible genes and by lymphocyte-endothelial cell cross-talk. The immunomodulating and antiangiogenic functions of IL-12 have provided the rationale for exploiting this cytokine as an anticancer agent. In contrast with the significant antitumor and antimetastatic activity of IL-12, documented in several preclinical studies, clinical trials with IL-12, used as a single agent, or as a vaccine adjuvant, have shown limited efficacy in most instances. More effective application of this cytokine, and of newly identified IL-12 family members (IL-23 and IL-27), should be evaluated as therapeutic agents with considerable potential in cancer patients.

Original languageEnglish
Pages (from-to)4677-4685
Number of pages9
JournalClinical Cancer Research
Volume13
Issue number16
DOIs
Publication statusPublished - Aug 15 2007

Fingerprint

Interleukin-12
Cytokines
Interleukin-27
Interleukin-23
Transformed Cell Line
Natural Killer T-Cells
Adaptive Immunity
Human Herpesvirus 4
Innate Immunity
Cellular Immunity
Antineoplastic Agents
B-Lymphocytes
Vaccines
Endothelial Cells
Clinical Trials
Lymphocytes
Genes
Neoplasms
Proteins

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Interleukin-12 : Biological properties and clinical application. / Del Vecchio, Michele; Bajetta, Emilio; Canova, Stefania; Lotze, Michael T.; Wesa, Amy; Parmiani, Giorgio; Anichini, Andrea.

In: Clinical Cancer Research, Vol. 13, No. 16, 15.08.2007, p. 4677-4685.

Research output: Contribution to journalArticle

Del Vecchio, Michele ; Bajetta, Emilio ; Canova, Stefania ; Lotze, Michael T. ; Wesa, Amy ; Parmiani, Giorgio ; Anichini, Andrea. / Interleukin-12 : Biological properties and clinical application. In: Clinical Cancer Research. 2007 ; Vol. 13, No. 16. pp. 4677-4685.
@article{e3c551f7e211478fa71219eee4f9e905,
title = "Interleukin-12: Biological properties and clinical application",
abstract = "Interleukin-12 (IL-12) is a heterodimeric protein, first recovered from EBV-transformed B cell lines. It is a multifunctional cytokine, the properties of which bridge innate and adaptive immunity, acting as a key regulator of cell-mediated immune responses through the induction of T helper 1 differentiation. By promoting IFN-γ production, proliferation, and cytolytic activity of natural killer and T cells, IL-12 induces cellular immunity. In addition, IL-12 induces an antiangiogenic program mediated by IFN-γ-inducible genes and by lymphocyte-endothelial cell cross-talk. The immunomodulating and antiangiogenic functions of IL-12 have provided the rationale for exploiting this cytokine as an anticancer agent. In contrast with the significant antitumor and antimetastatic activity of IL-12, documented in several preclinical studies, clinical trials with IL-12, used as a single agent, or as a vaccine adjuvant, have shown limited efficacy in most instances. More effective application of this cytokine, and of newly identified IL-12 family members (IL-23 and IL-27), should be evaluated as therapeutic agents with considerable potential in cancer patients.",
author = "{Del Vecchio}, Michele and Emilio Bajetta and Stefania Canova and Lotze, {Michael T.} and Amy Wesa and Giorgio Parmiani and Andrea Anichini",
year = "2007",
month = "8",
day = "15",
doi = "10.1158/1078-0432.CCR-07-0776",
language = "English",
volume = "13",
pages = "4677--4685",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "16",

}

TY - JOUR

T1 - Interleukin-12

T2 - Biological properties and clinical application

AU - Del Vecchio, Michele

AU - Bajetta, Emilio

AU - Canova, Stefania

AU - Lotze, Michael T.

AU - Wesa, Amy

AU - Parmiani, Giorgio

AU - Anichini, Andrea

PY - 2007/8/15

Y1 - 2007/8/15

N2 - Interleukin-12 (IL-12) is a heterodimeric protein, first recovered from EBV-transformed B cell lines. It is a multifunctional cytokine, the properties of which bridge innate and adaptive immunity, acting as a key regulator of cell-mediated immune responses through the induction of T helper 1 differentiation. By promoting IFN-γ production, proliferation, and cytolytic activity of natural killer and T cells, IL-12 induces cellular immunity. In addition, IL-12 induces an antiangiogenic program mediated by IFN-γ-inducible genes and by lymphocyte-endothelial cell cross-talk. The immunomodulating and antiangiogenic functions of IL-12 have provided the rationale for exploiting this cytokine as an anticancer agent. In contrast with the significant antitumor and antimetastatic activity of IL-12, documented in several preclinical studies, clinical trials with IL-12, used as a single agent, or as a vaccine adjuvant, have shown limited efficacy in most instances. More effective application of this cytokine, and of newly identified IL-12 family members (IL-23 and IL-27), should be evaluated as therapeutic agents with considerable potential in cancer patients.

AB - Interleukin-12 (IL-12) is a heterodimeric protein, first recovered from EBV-transformed B cell lines. It is a multifunctional cytokine, the properties of which bridge innate and adaptive immunity, acting as a key regulator of cell-mediated immune responses through the induction of T helper 1 differentiation. By promoting IFN-γ production, proliferation, and cytolytic activity of natural killer and T cells, IL-12 induces cellular immunity. In addition, IL-12 induces an antiangiogenic program mediated by IFN-γ-inducible genes and by lymphocyte-endothelial cell cross-talk. The immunomodulating and antiangiogenic functions of IL-12 have provided the rationale for exploiting this cytokine as an anticancer agent. In contrast with the significant antitumor and antimetastatic activity of IL-12, documented in several preclinical studies, clinical trials with IL-12, used as a single agent, or as a vaccine adjuvant, have shown limited efficacy in most instances. More effective application of this cytokine, and of newly identified IL-12 family members (IL-23 and IL-27), should be evaluated as therapeutic agents with considerable potential in cancer patients.

UR - http://www.scopus.com/inward/record.url?scp=34548067624&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548067624&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-07-0776

DO - 10.1158/1078-0432.CCR-07-0776

M3 - Article

C2 - 17699845

AN - SCOPUS:34548067624

VL - 13

SP - 4677

EP - 4685

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 16

ER -